The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter. MoonLake's ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Could the world’s best-selling drug have competition on the way? American pharmaceutical giant Bristol Myers Squibb agreed ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking ...

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Donaldson Company (NYSE: DCI) reported its Q3 FY25 results with sales rising 1.3% Y/Y to $940.1M, missing consensus. GAAP net ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...